# Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

> **NCT05905172** · PHASE3 · RECRUITING · sponsor: **Beijing Continent Pharmaceutical Co, Ltd.** · enrollment: 248 (estimated)

## Conditions studied

- Liver Fibrosis

## Interventions

- **DRUG:** Hydronidone capsules
- **DRUG:** The placebo capsules

## Key facts

- **NCT ID:** NCT05905172
- **Lead sponsor:** Beijing Continent Pharmaceutical Co, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-12
- **Primary completion:** 2028-06-20
- **Final completion:** 2028-10-20
- **Target enrollment:** 248 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905172, "Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05905172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*